Puma Biotechnology Inc. buy WatchMen
Start price
16.07.24
/
50%
€3.35
Target price
16.07.25
-
Performance (%)
-27.72%
Price
15.08.24
€2.42
Summary
This prediction is currently active. The prediction for Puma Biotechnology Inc. disappoints with a performance of -27.72%. This prediction currently runs until 16.07.25. The prediction end date can be changed by WatchMen at any time. WatchMen has 50% into this predictionPuma Biotechnology is a publicly traded biopharmaceutical company that develops innovative cancer therapies targeting the most aggressive and difficult-to-treat forms of the disease. Puma's lead product is Nerlynx, an oral medication approved for the treatment of HER2-positive breast cancer, and the company also has a number of other promising drugs in its pipeline. Founded in 2010, Puma is headquartered in Los Angeles, California, and its shares trade on the NASDAQ exchange under the ticker symbol PBYI.
Performance without dividends (%)
| Name | 1w |
|---|---|
| Puma Biotechnology Inc. | -30.936% |
| iShares Core DAX® | 2.821% |
| iShares Nasdaq 100 | 5.285% |
| iShares Nikkei 225® | 3.687% |
| iShares S&P 500 | 3.577% |
Comments by WatchMen for this prediction
In the thread Puma Biotechnology Inc. diskutieren
Buy Puma Biotechnology Inc.
Stopped prediction by WatchMen for Puma Biotechnology Inc.
Puma Biotechnology Inc.
Start price
Target price
Perf. (%)
€5.30
26.03.24
26.03.24
€10.00
26.03.25
26.03.25
-30.72%
16.07.24
16.07.24
